These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 26521338)
1. First Million-Dollar Syringe Could Be a Sight for Sore Eyes. Morrow T Manag Care; 2015 Sep; 24(9):38-9. PubMed ID: 26521338 [No Abstract] [Full Text] [Related]
2. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265 [No Abstract] [Full Text] [Related]
15. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations. Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600 [TBL] [Abstract][Full Text] [Related]
16. [RPE65-retinal Dystrophies: From the Spectrum of the Clinical Picture to Gene Therapy]. Stingl K; Priglinger C Klin Monbl Augenheilkd; 2024 Mar; 241(3):257-258. PubMed ID: 38508213 [No Abstract] [Full Text] [Related]
17. Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration). Battaglia Parodi M; La Spina C; Corradetti G; Berchicci L; Petruzzi G; Bandello F Dev Ophthalmol; 2016; 55():205-11. PubMed ID: 26502105 [TBL] [Abstract][Full Text] [Related]
18. Luxturna: FDA documents reveal the value of a costly gene therapy. Darrow JJ Drug Discov Today; 2019 Apr; 24(4):949-954. PubMed ID: 30711576 [TBL] [Abstract][Full Text] [Related]